Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gocatamig and Ifinatamab Deruxtecan in First-line Extensive Stage Small Cell Lung Cancer
NCT07227597Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2026
- Primary completion
- Nov 2030
- Modality
- Prophylactic Vaccines, Small Molecules, Antibody-Drug Conjugates (ADCs)
- Countries
- 13
01
Overview
A Phase 2 trial of gocatamig, ifinatamab deruxtecan in small cell lung cancer (SCLC), sponsored by Merck & Co.. Started Jan 2026; status: recruiting.
02
Drugs
gocatamigifinatamab deruxtecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07227597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07227597.